Artificial vision

Microdose Announces Gallery Partnership and Transformative Art Exhibition for the Upcoming Wonderland 2022

Retrieved on: 
Friday, October 28, 2022

Miami, Florida--(Newsfile Corp. - October 28, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is excited to announce its gallery partnership with collector's club 1of1 for the 2nd edition of Wonderland.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - October 28, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is excited to announce its gallery partnership with collector's club 1of1 for the 2nd edition of Wonderland.
  • The highly anticipated event is coming back to Miami on November 3-5th, 2022, at the Mana Wynwood Convention Center.
  • Microdose has teamed up with Le Guillou, a France-based visual creator, to create an immersive exhibition that challenges the mind to think further beyond expansion.
  • Wonderland is all about real-life events featuring high-quality programming in some of the world's most exciting locations and breath-taking venues.

DGAP-News: STEMMER IMAGING again defies global supply shortages with record figures in the first quarter - mid-term guidance raised to an EBITDA target margin of 13-16%

Retrieved on: 
Wednesday, May 11, 2022

At the same time, the company posted record revenue with another strong book-to-bill ratio of 1.2 despite the ongoing global supply shortages.

Key Points: 
  • At the same time, the company posted record revenue with another strong book-to-bill ratio of 1.2 despite the ongoing global supply shortages.
  • STEMMER IMAGING generated revenue of EUR 35.9 million in the reporting period (Q1 2021: EUR 31.2 million), the highest quarterly revenue in the company's history.
  • STEMMER IMAGING recorded growth in both order intake and revenue that exceeded the industry figures reported by the German Mechanical Engineering Industry Association (VDMA).
  • With a high level of expertise and value-added services STEMMER IMAGING additionally offers pre-configured subsystems dedicated to specifc applications.

DGAP-News: STEMMER IMAGING receives record order in the field of Artificial Vision

Retrieved on: 
Wednesday, January 12, 2022

Puchheim, January 12, 2022 - STEMMER IMAGING AG (ISIN DE000A2G9MZ9 / GSIN A2G9MZ ) received a record order for a technologically innovative follow-up development at the beginning of the year.

Key Points: 
  • Puchheim, January 12, 2022 - STEMMER IMAGING AG (ISIN DE000A2G9MZ9 / GSIN A2G9MZ ) received a record order for a technologically innovative follow-up development at the beginning of the year.
  • The order from the Sports & Entertainment segment comprises a combination of innovative machine vision solution supplemented by value-added services.
  • STEMMER IMAGING is thus once again benefiting from its clear positioning in this Artificial Vision segment.
  • symbolises the STEMMER IMAGING mission to make machine vision easy and accessible, empowering customers to deliver world-class solutions.

Second Sight Medical Products Announces Two-Year Results of its Orion Study

Retrieved on: 
Wednesday, May 12, 2021

b'Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSecond Sight\xe2\x80\x9d), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion).

Key Points: 
  • b'Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cSecond Sight\xe2\x80\x9d), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion).
  • The Study is a single arm six subject study at UCLA and Baylor College of Medicine.
  • All subjects are still enrolled in the Study and recent visual function and functional vision results continue to demonstrate that a majority of participants benefit from Orion.
  • No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the OrionĀ® Cortical Visual Prosthesis at UCLA

Retrieved on: 
Tuesday, September 22, 2020

Second Sight Medical Products Inc. (NASDAQ: EYES ), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion Visual Cortical Prosthesis System (Orion) at UCLA Medical Center (UCLA).

Key Points: 
  • Second Sight Medical Products Inc. (NASDAQ: EYES ), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion Visual Cortical Prosthesis System (Orion) at UCLA Medical Center (UCLA).
  • A total of six subjects have been implanted in the Orion Early Feasibility Study.
  • About Second Sight Medical Products Inc.
    Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston.